Clinical trial · Interventional
Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)
Phase II Study of EGFR Status Based Gefitinib Neoadjuvant Therapy in NSCLC Patients
NCT00986284CI-TRIAL-00020279suspendedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Lack of patients and some progressed disease soon after surgery
Summary
Brief summary (as posted)
This study aims to investigate the efficacy and safety of gefitinib as neoadjuvant therapy in stage IIIA NSCLC patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| gefitinib | Drug | Gefitinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Gefitinib, Neoadjuvant therapy
- description
- Patients with EGFR mutation will be recruited and treated with gefitinib.
- interventionNames
- Drug: gefitinib
Primary outcomes (1)
- measure
- Response Rate
- timeFrame
- 1 month
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients pathological diagnosed with NSCLC,with EGFR sensitive mutation; * Stage IIIA patients with technical operable disease evaluated by image and lab results; * Patients without chemotherapy or targeted-therapy before; * Inform Consent. Exclusion Criteria: * Patients with malignant tumor other than lung cancer; * Patients with other diseases such as cardiovascular disease that may hamper follow up; * Patients that may not coordinate well,judged by researcher.
References
Publications (0)
Data not yet available
No reference posted for this study.